Skip to site menu Skip to page content

Daily Newsletter

28 August 2023

Daily Newsletter

28 August 2023

GK Financing extends partnership with Methodist Hospital

The new agreement, lasting until 2037, involves upgrading the hospital's current Gamma Knife Perfexion system.

August 25 2023

GK Financing, a subsidiary of American Shared Hospital Services (ASHS), has extended its alliance with the community-based health system Methodist Hospital in Merrillville, Indiana, US, by another eight years.

The new agreement, lasting until 2037, involves upgrading the hospital's current Gamma Knife Perfexion system to Gamma Knife Esprit, Elekta's radiosurgery system.

Gamma Knife radiosurgery is a non-invasive technique that targets intracranial tumours with minimal impact on healthy tissue.

This upgrade is expected to offer enhanced clinical features, including frameless and frame-based workflows, advanced on-board CT imaging, and remote treatment planning capabilities.

ASHS CEO Peter Gaccione and GK Financing (GKF) president said: “Methodist Hospital has provided Gamma Knife radiosurgery for 20 years of which GKF and Methodist Hospital have been clinical partners since 2019 and we have seen their Gamma Knife programme grow and expand over that time. 

“GKF is extremely proud to be part of supporting the Neurosurgeons and Radiation Oncology teams as they upgrade to the latest Gamma Knife Esprit which will allow them to offer greater clinical treatments to patients.  

“In fact, this will be the fourth Esprit installed in the US, putting Methodist Hospital of Indiana in the forefront of treating cancer patients with the latest non-invasive radiosurgery technology.”

GK Financing, in partnership with Elekta, specialises in providing financial and technology solutions for Gamma Knife systems.

ASHS offers a range of creative financial solutions for cancer treatment centres and hospitals worldwide.

Digital transformation of the healthcare industry is driving the demand and development for precision and personalized medicine

Per GlobalData estimates, the precision and personalized medicine market is expected to achieve a CAGR of more than 43% between 2022 and 2029. The digital transformation of the healthcare industry is driving the market demand. For example, advances in biomarker testing with NGS are improving patient selection, use of AI in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close